HomeNewsBusinessOmicron may be less severe in young and old, but not 'mild': WHO

Omicron may be less severe in young and old, but not 'mild': WHO

Janet Diaz, WHO lead on clinical management, said early studies showed there was a reduced risk of hospitalisation from the variant first identified in southern Africa and Hong Kong in November compared with Delta.

January 06, 2022 / 22:37 IST
Story continues below Advertisement
Representative Image. (Source: Reuters)
Representative Image. (Source: Reuters)

The more infectious Omicron variant of COVID-19 appears to produce less severe disease than the globally dominant Delta strain, but should not be categorised as "mild", World Health Organization (WHO) officials said on Thursday.

Janet Diaz, WHO lead on clinical management, said early studies showed there was a reduced risk of hospitalisation from the variant first identified in southern Africa and Hong Kong in November compared with Delta.

Story continues below Advertisement

There appears also to be a reduced risk of severity in both younger and older people, she told a media briefing from WHO headquarters in Geneva.

The remarks on the reduced risks of severe disease chime with other data, including studies from South Africa and England, although she did not give further details about the studies or ages of the cases analysed.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show